Comparative Pharmacology
Head-to-head clinical analysis: SODIUM ZIRCONIUM CYCLOSILICATE versus SPS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SODIUM ZIRCONIUM CYCLOSILICATE versus SPS.
SODIUM ZIRCONIUM CYCLOSILICATE vs SPS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sodium zirconium cyclosilicate is a non-absorbed, inorganic, potassium-selective cation exchanger that binds potassium ions in the gastrointestinal tract, thereby reducing the absorption of potassium and facilitating its fecal excretion. It exchanges sodium and hydrogen for potassium in the gut lumen.
SPS (sodium polystyrene sulfonate) is a cation-exchange resin that exchanges sodium ions for potassium ions in the gastrointestinal tract, primarily in the colon, thereby reducing serum potassium levels.
5 g orally three times daily.
15-60 g orally 1-4 times daily; administer as a suspension in water or juice. Alternatively, 30-50 g rectally as a retention enema every 6 hours.
None Documented
None Documented
Not applicable as the drug acts locally in the GI tract without systemic absorption; clinical effect persists for duration of dosing.
Not applicable; SPS acts locally in the gastrointestinal tract and does not undergo systemic absorption. No terminal half-life can be defined.
Primarily eliminated unchanged in feces (>99%); negligible renal excretion (<1%) as the drug is not absorbed systemically.
SPS (sodium polystyrene sulfonate) is a cation-exchange resin that is not absorbed systemically. It is excreted entirely in the feces, with no renal or biliary elimination. The resin-bound potassium is eliminated via the gastrointestinal tract.
Category C
Category C
Potassium Binder
Potassium Binder